Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Cash (2016 - 2026)

Cytosorbents filings provide 15 years of Change in Cash readings, the most recent being -$1.3 million for Q4 2025.

  • On a quarterly basis, Change in Cash rose 46.46% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 65.94% increase, with the full-year FY2025 number at -$2.0 million, up 65.94% from a year prior.
  • Change in Cash hit -$1.3 million in Q4 2025 for Cytosorbents, up from -$2.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $5.6 million in Q4 2023 to a low of -$12.9 million in Q2 2022.
  • Median Change in Cash over the past 5 years was -$2.9 million (2021), compared with a mean of -$3.2 million.
  • Biggest five-year swings in Change in Cash: plummeted 349.73% in 2022 and later skyrocketed 1465.95% in 2023.
  • Cytosorbents' Change in Cash stood at -$7.2 million in 2021, then skyrocketed by 94.35% to -$407672.0 in 2022, then skyrocketed by 1465.95% to $5.6 million in 2023, then tumbled by 143.17% to -$2.4 million in 2024, then surged by 46.46% to -$1.3 million in 2025.
  • The last three reported values for Change in Cash were -$1.3 million (Q4 2025), -$2.7 million (Q3 2025), and -$1.4 million (Q2 2025) per Business Quant data.